Novel strategies for hydrocortisone replacement

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 2, 2009, Pages 221-232

  Debono, M ^a   Price, J Newell ^a   Ross, Richard J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

adrenal insufficiency; circadian rhythm; congenital adrenal hyperplasia; modified release hydrocortisone

Indexed keywords

CORTISONE ACETATE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; PREDNISOLONE;

ADRENAL INSUFFICIENCY; AREA UNDER THE CURVE; BEDTIME DOSAGE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; CUSHINGOID SYNDROME; DELAYED RELEASE FORMULATION; DISEASE CONTROL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; EVENING DOSAGE; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERTENSION; LOW DRUG DOSE; MORNING DOSAGE; MORTALITY; OPTIMAL DRUG DOSE; OSTEOPOROSIS; PATIENT MONITORING; PREDICTION; PREVALENCE; PROTEIN DEGRADATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIMULATION; SINGLE DRUG DOSE; SLEEP; SUBSTITUTION THERAPY; SUSTAINED RELEASE FORMULATION;

ADRENAL INSUFFICIENCY; CIRCADIAN RHYTHM; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE; MONITORING, PHYSIOLOGIC;

EID: 66149179140     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.09.010     Document Type: Review

References (48)

1. Krieger D.T., Allen W., Rizzo F., et al. Characterization of the normal temporal pattern of plasma corticosteroid levels. The Journal of Clinical Endocrinology and Metabolism 32 (1971) 266-284
2. Weitzman E.D., Fukushima D., Nogeire C., et al. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. The Journal of Clinical Endocrinology and Metabolism 33 (1971) 14-22
3. Darzy K.H., and Shalet S.M. Absence of adrenocorticotropin (ACTH) neurosecretory dysfunction but increased cortisol concentrations and production rates in ACTH-replete adult cancer survivors after cranial irradiation for nonpituitary brain tumors. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 5217-5225
4. Howlett T.A. An assessment of optimal hydrocortisone replacement therapy. Clinical Endocrinology 46 (1997) 263-268
5. Groves R.W., Toms G.C., Houghton B.J., et al. Corticosteroid replacement therapy: twice or thrice daily?. Journal of the Royal Society of Medicine 81 (1988) 514-516
6. Mah P.M., Jenkins R.C., Rostami-Hodjegan A., et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clinical Endocrinology 61 (2004) 367-375
7. Besser G.M., and Jeffcoate W.J. Endocrine and metabolic diseases. Adrenal diseases. British Medical Journal 1 (1976) 448-451
8. Hahner S., Loeffler M., Fassnacht M., et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 3912-3922
9. Lovas K., Loge J.H., and Husebye E.S. Subjective health status in Norwegian patients with Addison's disease. Clinical Endocrinology 56 (2002) 581-588
10. Peacey S.R., Guo C.Y., Robinson A.M., et al. Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clinical Endocrinology 46 (1997) 255-261
11. Filipsson H., Monson J.P., Koltowska-Haggstrom M., et al. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 3954-3961
12. Bergthorsdottir R., Leonsson-Zachrisson M., Oden A., et al. Premature mortality in patients with Addison's disease: a population-based study. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 4849-4853
13. Mills J.L., Schonberger L.B., Wysowski D.K., et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. The Journal of Pediatrics 144 (2004) 430-436
14. White P.C., and Speiser P.W. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews 21 (2000) 245-291
15. Debono M., and Ross R.J. Doses and steroids to be used in primary and central hypoadrenalism. Annales D'endocrinologie 68 (2007) 265-267
16. Merza Z., Rostami-Hodjegan A., Memmott A., et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clinical Endocrinology 65 (2006) 45-50
17. Lovas K., and Husebye E.S. Continuous subcutaneous hydrocortisone infusion in Addison's disease. European Journal Of Endocrinology/European Federation of Endocrine Societies 157 (2007) 109-112
18. Newell-Price J., Whiteman M., Rostami-Hodjegan A., et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clinical Endocrinology 68 (2008) 130-135
19. Skrtic S.H.L., Nilsson A., Bergthorsdottir R., et al. Improved glucocorticoid replacement therapy by a novel oral hydrocortisone modified-release tablet (oral communication) 9th European Congress of Endocrinology (2007), Hungary, Budapest 28 April - 2 May
20. Rubin R.P. A brief history of great discoveries in pharmacology: in celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics. Pharmacological Reviews 59 (2007) 289-359
21. Lovas K., and Husebye E.S. Replacement therapy for Addison's disease: recent developments. Expert Opinion on Investigational Drugs 17 (2008) 497-509
22. Derendorf H., Mollmann H., Barth J., et al. Pharmacokinetics and oral bioavailability of hydrocortisone. Journal of Clinical Pharmacology 31 (1991) 473-476
23. Esteban N.V., and Yergey A.L. Cortisol production rates measured by liquid chromatography/mass spectrometry. Steroids 55 (1990) 152-158
24. Kerrigan J.R., Veldhuis J.D., Leyo S.A., et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. The Journal of Clinical Endocrinology and Metabolism 76 (1993) 1505-1510
25. Linder B.L., Esteban N.V., Yergey A.L., et al. Cortisol production rate in childhood and adolescence. The Journal of Pediatrics 117 (1990) 892-896
26. Oelkers W. Adrenal insufficiency. The New England Journal of Medicine 335 (1996) 1206-1212
27. Arlt W., Rosenthal C., Hahner S., et al. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clinical Endocrinology 64 (2006) 384-389
28. Trainer P.J., and Besser G.M. Barts endocrine protocols (1995), Churchill Livingstone International, Edinburgh
29. Lockhart D.A. Drug interactions: cytochrome P450 drug interaction table (2007), Indiana University School of Medicine. http://medicine.iupui.edu/flockhart/table.htm [accessed 08.09.08]
30. Trainer P.J., McHardy K.C., Harvey R.D., et al. Urinary free cortisol in the assessment of hydrocortisone replacement therapy. Hormone and Metabolic Research 25 (1993) 117-120
31. Thomson A.H., Devers M.C., Wallace A.M., et al. Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. Clinical Endocrinology 66 (2007) 789-796
32. Sauve B., Koren G., Walsh G., et al. Measurement of cortisol in human hair as a biomarker of systemic exposure. Clinical and Investigative Medicine 30 (2007) E183-E191
33. Arlt W., and Allolio B. Adrenal insufficiency. Lancet 361 (2003) 1881-1893
34. Lovas K., Husebye E.S., Holsten F., et al. Sleep disturbances in patients with Addison's disease. European Journal of Endocrinology/European Federation of Endocrine Societies 148 (2003) 449-456
35. Zelissen P.M., Croughs R.J., van Rijk P.P., et al. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Annals of Internal Medicine 120 (1994) 207-210
36. McConnell E.M., Bell P.M., Ennis C., et al. Effects of low-dose oral hydrocortisone replacement versus short-term reproduction of physiological serum cortisol concentrations on insulin action in adult-onset hypopituitarism. Clinical Endocrinology 56 (2002) 195-201
37. Plat L., Byrne M.M., Sturis J., et al. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. The American Journal of Physiology 270 (1996) E36-E42
38. Girgis R., and Winter J.S. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism 82 (1997) 3926-3929
39. Silva I.N., Kater C.E., Cunha C.F., et al. Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood 77 (1997) 214-218
40. Weintrob N., Dickerman Z., Sprecher E., et al. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height. European Journal of Endocrinology/European Federation of Endocrine Societies 136 (1997) 188-195
41. Cavallo A., Corn C., Bryan G.T., et al. The use of plasma androstenedione in monitoring therapy of patients with congenital adrenal hyperplasia. The Journal of Pediatrics 95 (1979) 33-37
42. Riepe F.G., and Sippell W.G. Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Reviews in Endocrine & Metabolic Disorders 8 (2007) 349-363
43. Laureti S., Vecchi L., Santeusanio F., et al. Is the prevalence of Addison's disease underestimated?. The Journal of Clinical Endocrinology and Metabolism 84 (1999) 1762
44. Lovas K., and Husebye E.S. High prevalence and increasing incidence of Addison's disease in western Norway. Clinical Endocrinology 56 (2002) 787-791
45. Willis A.C., and Vince F.P. The prevalence of Addison's disease in Coventry, UK. Postgraduate Medical Journal 73 (1997) 286-288
46. Regal M., Paramo C., Sierra S.M., et al. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clinical Endocrinology 55 (2001) 735-740
47. Daly A.F., Rixhon M., Adam C., et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 4769-4775
48. Moeller H. Chronopharmacology of hydrocortisone and 9 alpha-fluorhydrocortisone in the treatment for congenital adrenal hyperplasia. European Journal of Pediatrics 144 (1985) 370-373